This is a positive clinical proof-of-concept for Alpha DaRT in glioblastoma outside the U.S., but it is a single-patient case under a broad-access protocol, not a controlled trial. Traders should watch for enrollment updates and data from the U.S. REGAIN trial, as well as any subsequent regulatory or partnership developments that could de-risk the program.
DRTS drugs
DRTS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 24 $10.05entry
- T+1 · 5mo ago +11.14%α +11.00% · $11.17
- T+5 · 5mo ago +25.77%α +24.06% · $12.64
- T+20 · 4mo ago +29.45%α +27.52% · $13.01
- T+60 · 2mo ago +54.13%α +51.29% · $15.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau announced the first-ever treatment of a recurrent glioblastoma patient outside the U.S. using its Alpha DaRT technology at Hadassah University Medical Center in Israel. The procedure was completed safely without unexpected complications, marking the first international clinical application of the brain-specific delivery system and adding momentum to the ongoing U.S. REGAIN trial.
Key Facts
- First recurrent glioblastoma patient treated with Alpha DaRT outside the U.S., and first in Israel, at Hadassah University Medical Center.
- Procedure used proprietary brain applicator with real-time stereotactic neuro-navigation via a single minimally-invasive burr hole.
- Patient was a 77-year-old male with recurrent glioblastoma following surgery and radiation therapy; procedure completed safely without unexpected complications.
- Treatment was under the ALL clinical protocol, a broad-access study at Hadassah open to patients with solid tumors amenable to Alpha DaRT.
- The company references its multicenter U.S. Recurrent GBM REGAIN trial, which is continuing recruitment following interim results and FDA clearance to proceed to full enrollment with two new U.S. academic centers.
Financial Impact
No financial figures provided; clinical milestone with no revenue or cost data disclosed.
Risk Factors
- Single-patient case under a broad-access protocol; no controlled efficacy data provided.
- Glioblastoma is a highly aggressive disease; safety and efficacy in larger populations remain unproven.
- Company is pre-revenue and will require additional capital to fund ongoing trials and operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-071076 |
| Document: ea029546701ex99-1.htm | 0001213900-26-071076 |
| Document: 0001213900-26-071076-index-headers.html | 0001213900-26-071076 |
| Document: 0001213900-26-071076-index.html | 0001213900-26-071076 |
| Document: 0001213900-26-071076.txt | 0001213900-26-071076 |
Track record
25 reports on DRTS
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 11 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers